

Attorney Docket No.: 5443.424-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Cherry et al.

Application No.: To be assigned

Group Art Unit: To be assigned

Filed: June 29, 2000

Examiner: To be assigned

For: Maltogenic Alpha-Amylase Variants

jc714 U.S. PTO
09/607142
06/29/00

#2
SJC
11/11/00

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. Copies of references were filed with USSN 09/386,607 filed on August 31, 1999, the benefit of which is claimed under 35 USC 120.

The references are as follows:

1. Kim et al., Biochemistry and Molecular Biology International, Vol. 41, No. 2, pgs. 227-234 (1997);
2. Sin et al., Journal of Biotechnology, Vol. 32, pgs. 283-288 (1994);


3. Penninga et al., *Biochemistry*, Vol. 34, pgs. 3368-3376 (1995);
4. *Biochemical Journal*, Vol. 316, pgs. 695-696 (1996);
5. EP 0 120 693;
6. Christophersen et al., *Starch/Stärke*, Vol. 50, No. 1, pgs. 39-45 (1998);
7. Bernard Henrissat, *Biochem. J.*, Vol. 280, pgs. 309-316 (1991);
8. Tachibana et al., *Journal of Fermentation and Bioengineering*, Vol. 83, No. 6, pgs. 540-548 (1997);
9. Norman et al., *Denpun Kagaku*, Vol. 39, No. 2, pgs. 101-108 (1992);
10. WO 89/03421;
11. WO 96/33267;
12. Hofmann et al., *J. Mol. Biol.*, Vol. 209, pgs. 793-800 (1989);
13. Lawson et al., *J. Mol. Biol.*, Vol. 236, pgs. 590-600 (1994);
14. Strokopytov et al., *Biochemistry*, Vol. 34, pgs. 2234-2240, (1995);
15. Knechtel et al., *J. Mol. Biol.*, Vol. 256, pgs. 611-622 (1996);
16. PCT/DK 99/00088;
17. WO 96/23874;
18. WO 97/43424;
19. WO 97/41213;
20. Boel et al., *Biochemistry*, Vol. 29, pgs. 6244-6249 (1990);
21. Machius et al., *J. Mol. Biol.*, Vol. 246, pgs. 545-559 (1995);
22. Chang et al., *J. Mol. Biol.*, Vol. 229, pgs. 235-238 (1993);
23. Kubota et al., *Denpun Kagaku*, Vol. 38, No. 2, pgs. 141-146 (1991);
24. Klein et al., *J. Mol. Biol.*, Vol. 217, pgs. 737-750 (1991);
25. Birte Svensson, *Plant Molecular Biology*, Vol. 25, pgs. 141-157 (1994);
26. Abstract (sequence listing) of Swiss application no. P19531.
27. Diderichsen et al., *FEMS Microbiology Letters*, Vol. 56, pgs. 53-60 (1988);
28. Wind et al., *Eur. J. Biochem.*, Vol. 253, pgs. 598-605 (1998);
29. Dalmia et al., *Biotechnology and Bioengineering*, Vol. 47, pgs. 575-584 (1995);
30. Jespersen et al., *Biochem. J.*, Vol. 280, pgs. 51-55 (1991);
31. del-Rio et al., *Febs Letters*, Vol. 416, pgs. 221-224 (1997);
32. Holm et al., *Protein Engineering*, Vol. 3, pgs. 181-191 (1990); and
33. Janacek et al., *Febs* 11085, Vol. 304, pgs. 1-3 (1992).

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed on filing date of application. Therefore, no fee is due.

Respectfully submitted,

Date: June 29, 2000


Elias J. Lambiris, Reg. No. 33,728
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123